EHC_subbed.qxp 12/2/09 15:09 Page 27
Haemophilia Treatment – Current and Future Challenges
as well as similar tolerance levels to its pegylated liposome-free blind multicentre study across 66 treatment centres in 14 countries will
counterpart (see Table 2).
56–59
Notably, the development of inhibitors randomise patients to receive either BAY 79-4980 at 35IU/kg once a
in subjects receiving BAY 79-4980 has yet to be observed. A phase II week or rFVIII three times a week over the course of one year. With
study recently began in August 2008 to determine whether once- promising safety and efficacy data thus far, it is hoped that this new
weekly administration of BAY 79-4980 is tolerable and sufficient to development of rFVIII-SF in combination with PEGylated liposomes will
prevent bleeds in patients with severe haemophilia A. This double- usher in the next era of progress in haemophilia treatment. ■
1. Berntorp E, Astermark J, Björkman S, et al., Consensus haemophilia A, Haemophilia 2003;9:38–49. 40. Brackmann HH, Gormsen J, Massive factor-VIII infusion in
perspectives on prophylactic therapy for haemophilia: 21. Lusher J, Abildgaard C, Arkin S, et al., Human recombinant haemophiliac with factor-VIII inhibitor, high responder,
summary statement, Haemophilia, 2003;9(Suppl 1):1–4. DNA-derived antihemophilic factor in the treatment of Lancet, 1977;2:933.
2. Nilsson IM, Hedner U, Ahlberg A, Haemophilia prophylaxis in previously untreated patients with hemophilia A: final report 41. Freiburghaus C, Berntorp E, Ekman M, et al., Tolerance
Sweden, Acta Paediatr Scand, 1976;65:129–35. on a hallmark clinical investigation, J Thromb Haemost, induction using the Malmö treatment model 1982–1995,
3. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al., 2004;2:574–83. Haemophilia, 1999;5:32–9.
The effects of postponing prophylactic treatment on long- 22. Kreuz W, Gill JC, Rothschild C, et al., Full-length sucrose- 42. Smith FP, Spence KJ, Walters EL, et al., Immune tolerance
term outcome in patients with severe hemophilia, Blood, formulated recombinant factor VIII for treatment of previously therapy for haemophilia A patients with acquired factor VIII
2002;99:2337–41. untreated or minimally treated young children with severe alloantibodies: comprehensive analysis of experience at a
4. Nilsson IM, Berntorp E, Löfqvist T, et al., Twenty-five years’ haemophilia A, Results of an international clinical single institution, Thromb Haemost, 1999;81:35–8.
experience of prophylactic treatment in severe hemophilia A investigation, Thromb Haemost, 2005;93:457–67. 43. Rocino A, Papa M, Capasso F, et al., Immune tolerance
and B, J Intern Med, 1992;232:25–32. 23. Goudemand J, Treatment of patients with inhibitors: cost induction in haemophilia A patients with high responding
5. Berntorp E, Prophylactic therapy for haemophilia: early issues, Haemophilia, 1999;5:397–401. inhibitors to factor VIII : experience at a single institution,
experience, Haemophilia, 2003; 9(Suppl. 1):5–9. 24. Aledort LM, Dimichele DM, Inhibitors occur more frequently Haemophilia, 2001;7:33–8.
6. Feldman BM, Pai M, Rivard GE, et al., Tailored prophylaxis in in African-American and Latino haemophiliacs, Haemophilia, 44. Gruppo RA, Valdez LP, Stout RD, Induction of immune
severe hemophilia A: interim results from the first 5 years of 1998;4:68. tolerance in patients with hemophilia A and inhibitors, Am J
the Canadian Hemophilia Primary Prophylaxis Study, J Throm 25. Astermark J, Berntorp E, White GC, et al., The Malmö Pediatr Hematol Oncol, 1992;14:82–7.
Haemost, 2006;4:1228–36. International Brother Study (MIBS): further support for 45. Mauser-Bunschoten EP, Rosendaal FR, Niewenhuis HK, et
7. Petrini P, Identifying and overcoming barriers to prophylaxis genetic predisposition to inhibitor development in hemophilia al., Clinical course of factor VIII inhibitors developed after
in the management of haemophilia, Haemophilia, patients, Haemophilia, 2001;7:267–72. exposure to a pasteurized Dutch concentrate compared to
2007;13(Suppl. 2):16–22. 26. Oldenburg J, El-Maarri O, Schwaab R, Inhibitor development classic inhibitors of hemophilia A, Thromb Haemost,
8. World Federation of Hemophilia, Guidelines for the in correlation to factor VIII genotypes, Haemophilia, 1994;71:35–8.
management of hemophilia, 2005. Available at: 2002;8(Suppl. 2):23–9. 46. Brackmann HH, Oldenburg J, Schwaab R, Immune tolerance
www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/ 27. Astermark J, Oldenburg J, Pavlova A, et al., Polymorphisms in for the treatment of factor-VIII inhibitors – twenty years
Gudelines_Mng_Hemophilia.pdf (last accessed 13 October the IL10 but not the IL1beta and IL4 genes are associated ‘Bonn protocol’, Vox Sang, 1996;70(Suppl. 1):30–35.
2008). with inhibitor development in patients with hemophilia A, 47. Immune Tolerance Induction Study. Available at:
9. Giangrande PL, Adverse events in the prophylaxis of Blood, 2006;107:3167–72. www.itistudy.com
haemophilia, Haemophilia, 2003;9(Suppl. 1):50–54, 28. Astermark J, Basic aspects of inhibitors to factors VIII and IX 48. Morfini M, Auerswald G, Kobelt RA, et al., Prophylactic
discussion 55–6. and the influence of non-genetic risk factors, Haemophilia, treatment of haemophilia patients with inhibitors: clinical
10. Giangrande PL, KOGENATE Bayer study group, Safety and 2006;12(Suppl. 6):8–13. experience with recombinant factor VIIa in European
efficacy of KOGENATE Bayer in previously untreated patients 29. Astermark J, Wang X, Oldenburg J, et al., Polymorphyisms in Haemophilia Centres, Haemophilia, 2007;13:502–7.
(PUPs) and minimally treated patients (MTPs), Haemophilia, the CTLA-4 gene and inhibitor development in patients with 49. Brackmann HH, Effenberger W, Hess L, et al., Immune
2002;8(Suppl. 2):19–22. severe hemophilia A, J Thromb Haemost, 2007;5:263–5. tolerance induction: a role for recombinant activated factor
11. Gouw SC, van der Bom JG, van den Berg M for the CANAL 30. Lorenzo JI, Lopez A, Altisent C, et al., Incidence of factor VIII VII (rFVIIa)?, Eur J Haematol Suppl, 1998;63:18–23.
Study Group, Treatment-related risk factors of inhibitor inhibitors in severe haemophilia: the importance of patient 50. Kreuz W, Ehrenforth S, Funk M, et al., Immune-tolerance
development in previously untreated patients with hemophilia age, Br J Haematol, 2001;113:600–603. therapy in paediatric haemophiliacs with factor VIII inhibitors:
A: the CANAL cohort study, Blood, 2007;109:4648–54. 31. van der Bom JG, Mauser-Bunschoten EP, Fischer K, et al., 14 years follow-up, Haemophilia, 1995;1:24–32.
12. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al., Age at first treatment and immune tolerance to factor VIII in 51. Lambert T, Clinical Experience of ITI in overcoming inhibitor
Prophylaxis versus episodic treatment to prevent joint disease severe hemophilia, Thromb Haemost, 2003;89:475–9. development, Presented at the 21st Annual European
in boys with severe hemophilia, N Engl J Med, 32. Morado M, Villar A, Jiménez Yuste V, et al., Prophylactic Haemophilia Consortium, Dublin, Ireland, 12–14 September
2007;357:535–44. treatment effects on inhibitor risk: experience in one centre, 2008.
13. Hemophilia: Information System (HemIS) registry, 2006 Haemophilia, 2005;11:79–83. 52. Powell JS, Liposomal approach towards the development of a
annual report, unpublished. 33. Goudemand J, Inhibitor development in haemophilia A: the longer-acting factor VIII, Haemophilia, 2007;13(Suppl.
14. Gringeri A, von Mackensen S, Auerswald G, et al., Health role of von Willebrand factor/factor VIII concentrates, 2):23–8.
status and health-related quality of life of children with Haemophilia, 2007;13(Suppl. 5):47–51. 53. Pan J, Liu T, Kim J-Y, et al., Enhanced efficacy of
haemophilia from six West European countries, Haemophilia, 34. Escurioloa Ettingshausen C, Kreuz W, Recombinant vs. recombinant factor VIII in non-covalent complex with
2004;10(Suppl. 1):26–33. Plasma-derived products, especially those with intact VWF, PEGylated liposome in hemophilia A mice, Blood,
15. Richards M, Altisent C, Batorova A, et al., Should prophylaxis regarding inhibitor development, Haemophilia, 2007;110:3149.
be used in adolescent and adult patients with severe 2006;12:102–6. 54. Baru M, Carmel-Goren L, Barenholz Y, et al., Factor VIII
haemophilia? An European survey of practice and outcome 35. von Auer CH, Oldenburg J, von Depka M, et al., Inhibitor efficient and specific non-covalent binding to PEGylated
data, Haemophilia, 2007;13:473–9. development in patients with hemophilia A after continuous liposomes enables prolongation of its circulation time and
16. Tagliaferri A, Franchini M, Coppola A, et al., Effects of infusion of FVIII concentrates, Ann N Y Acad Sci, 2005;1051: haemostatic efficacy, Thromb Haemost, 2005;93:1061–8.
secondary prophylaxis started in adolescent and adult 498–505. 55. Spira J, Plyushch OP, Andreeva TA, et al., Prolonged
haemophiliacs, Haemophilia, 2008;14:945-951. 36. Chalmers EA, Williams MD, Richards M, et al., Early FVIII bleeding-free period following prophylactic infusion of
17. Wight J, Paisley S, The epidemiology of inhibitors in exposure and subsequent inhibitor development in children recombinant factor VIII reconstituted with pegylated
haemophilia A: a systematic review, Haemophilia, with severe haemophilia A, J Thromb Haemost, 2005;3, liposomes, Blood, 2006;108:3668–73.
2003;9:418–35. abstract OR092. 56. Powell JS, Nugent DJ, Harrison JA, et al., Safety and
18. Gruppo R, Chen H, Schroth P, et al. for the Recombinate PUP 37. Fontes E, Carvalho S, Amorim L, Age at the beginning of pharmacokinetics of a recombinant factor VIII with pegylated
Study Group, Safety and Immunogenicity of recombinant factor VIII replacement is not a risk factor for inhibitor liposomes in severe hemophilia A, J Thromb Haemost,
factor VIII (Recombinate™) in previously untreated patients development in hemophilia A, Haemophilia, 2004;10:(Suppl. 2008;6:277–83.
(PUPs): a 7.3 year update, Haemophilia, 1998;4:228, abstract 3), abstract 12OC14. 57. Szebeni J, Complement activation-related pseudoallergy: a
291. 38. Kreuz W, Auerswald G, Budde U, et al., Inhibitor incidence in new class of drug-induced acute immune toxicity, Toxicology,
19. Rothschild C, Laurian Y, Satre EP, et al., French previously previously untreated patients (PUP) with hemophilia A and B 2005;216:106–21.
untreated patients with severe hemophilia A after exposure – a 10-year follow up of the prospective multicenter study, 58. Spira J, Plyushch OP, Andreeva TA, et al., Evaluation of
to recombinant factor VIII: incidence of inhibitor and Blood, 2004;104, abstract 3983. liposomal dose in recombinant factor VIII reconstituted with
evaluation of immune tolerance, Thromb Haemost, 39. Gouw SC, van der Bom JG, Auerswald Gunter, et al., pegylated liposomes for the treatment of patients with severe
1998;80:779–83. Recombinant versus plasma-derived factor VIII products and haemophilia A, Thromb Haemost, 2008;100:429–34.
20. Lusher JM, Lee CA, Kessler CM, et al. for the Refacto phase 3 the development of inhibitors in previously untreated patients 59. Martinowitz U, Lalezari S, Luboshitz, et al., Infusion rates of
study group, The safety and efficacy of B-domain deleted with severe hemophilia A: the CANAL cohort study, Blood, recombinant FVIII-FS withi PEGylated liposomes in
recombinant factor VIII concentrate in patients with severe 2007;109:4693–7. haemophilia A, Haemophilia, 2008;14:1122–4.
EUROPEAN HAEMATOLOGY 27
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100